Exact Sciences Corporation (NASDAQ: EXAS) (“Exact Sciences”), a leading provider of cancer screening and diagnostic tests, today announced that its stockholders voted to approve the proposed ...
To lower agricultural emissions, policymakers and communities first need to pinpoint the sources—not just by country but crop by crop, field by field. In a study published in Nature Climate Change, ...
The State Supreme Court allowed a spring statewide referendum that is necessary for Democrats to redraw Virginia’s congressional map before the midterm elections. By Tim Balk Virginia’s top court on ...
Users are sharing deeply personal memories of loved ones and the lasting marks they’ve left behind Ashley Vega is a writer-reporter at PEOPLE. She has been working at PEOPLE since 2024. Her work has ...
A rapidly strengthening coastal storm is expected to develop this weekend and bring heavy snow, strong winds and coastal flooding to the Southeast amid an outbreak of deadly cold temperatures. As the ...
Attempting to copy something exactly often feels like a matter of careful observation, yet accuracy consistently falls apart without deeper understanding. This video explains why relying only on what ...
Pour one out for the ancient MetroCard and its equally old cousin, the PATH SmartLink card. The beginning of the end for these longtime ways to pay fares on the bi-state PATH system came Thursday when ...
Abbott is getting into cancer testing with its $21 billion acquisition Exact Sciences, the maker of the game-changing colorectal cancer test Cologuard. Abbott markets well-known diagnostics for ...
Exact Sciences Corporation stock surged after Abbott Laboratories announces a $21bn acquisition at $105 per share, driven by Exact's cancer diagnostics leadership. Exact Sciences boasts strong revenue ...
Abbott to buy Exact Sciences in $23 billion deal Exact's flagship colorectal cancer test to join Abbott's portfolio Abbott eyes international expansion for Exact's tests Aims for broad reimbursement ...
Forbes contributors publish independent expert analyses and insights. Bruce Japsen writes about healthcare business and policy. Abbott Laboratories $21 billion deal to acquire cancer test maker Exact ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results